All Posts by
Read the abstract for “Can Engagement aid in design and accrual on Clinical Trials? Observations from COMPPARE – A Prospective Comparison of Outcomes with Proton and Photon Radiation in Prostate Cancer” here!…
Two-year findings were discussed at ASCO in Chicago on May 31, but assessing long-term comparative outcomes like disease control, late toxicity and secondary cancers will need longer follow-up.
When you volunteered for COMPPARE, you might have heard about something its PCD. But what does that mean for you, really?…
Our most critical insights will come years after treatment ends, as long-term follow-up is essential to understanding lasting effects and benefits.
Learn about the importance of the Primary Completion Date, an exciting alternative to MRIs for prostate cancer biopsies, and more. …
After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022 at 11:59 p.m. EST. “This is an important milestone and we appreciate the patients who have agreed to participate and all of the hard work on the part of…
The COMPPARE Coordinating Center announced today that the study has enrolled its 1,000th photon prostate cancer patient to reach 67% of its photon cohort goal. COMPPARE Partner Site University of Maryland enrolled the 1,000th patient, followed closely by UNC REX Healthcare, Raleigh, NC, which…
If you are a man between the ages of 55 and 69, September is a good time to schedule a prostate screening, one that includes both a PSA blood test and prostate examination. Consider the numbers: Prostate cancer is the most common genitourinary cancer treated by a urologist and the…
The COMPPARE Coordinating Center announced today that the study has enrolled its 1,500th proton prostate cancer patient and has closed enrollment for the proton cohort. This goal was achieved in advance of the projected completion date of July 31, 2022. The proton cohort is divided into two groups: Pragmatic and…
The COMPPARE Coordinating Center announced today that the study achieved 75% enrollment on May 3, 2022. COMPPARE realized both a remarkable overall accrual rate and a exceptional accrual rate of minorities, despite the ongoing challenges presented by COVID-19. In fact, the study stands to become a model for patient-centric clinical…
